Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Instagram Outage Disrupts Thousands of U.S. Users 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Johnson & Johnson confirmed on Monday, Jan. 8, that it is buying Ambrx cancer treatment developer Ambrx Biopharma for $2 billion. It will be paid in cash, and this acquisition deal comes as the company seeks to fill in a revenue gap expected to come in 2025 when its Stelara drug starts facing generic competition for treating an autoimmune disease called psoriasis.
Move to Diversify and Increase Revenues
According to CNBC, Johnson & Johnson announced the acquisition at the start of the annual JPMorgan Healthcare Conference. This move is seen as J&J’s entry into the ADC market that has recently been infiltrated by its rivals like Merck, Pfizer, and AbbVie, who have also acquired smaller drugmakers to bet on ADC.
The deal is a strategic decision since its top-selling Stelara drug is expected to face competition in the coming years. This means the company is preparing to produce new treatments that can provide revenues in case of a sales slowdown. The deal simply presents new opportunities for Johnson & Johnson, not only financially but also in having the chance to deliver new drugs that can transform cancer treatment and improve patients’ lives.
Terms of the Buyout Deal
As the agreement indicates, Johnson & Johson will pay $28 for every share of Ambrx or double the company’s Friday closing price, which was settled at $13.63. The New Brunswick, New Jersey-headquartered pharma and medical technologies company expects to complete the deal within the first two quarters of this year.
“Ambrx’s ADC technology offers unique advantages in the conjugation of stable antibodies and cytotoxic linker payloads, which results in engineered ADCs that effectively kill cancer cells and limit toxicities,” Johnson & Johnson Innovative Medicines’ area head of global therapeutic, Yusri A. Elsayed, M.D., M.H.Sc., Ph.D., said in a press release. “The results seen to date with ARX517 in mCRPC are promising and represent a potential first- and best-in-class targeted therapy for the treatment of this aggressive disease.”
The innovative medicine unit’s area leader for prostate cancer disease, Margaret Yu, M.D., further commented, “With a median overall survival of less than two years and novel hormonal therapies moving earlier in the disease, significant unmet need remains in the treatment of mCRPC, we see a unique opportunity to harness the potential of this innovative ADC platform, and with our deep understanding of prostate cancer, deliver a targeted PSMA therapeutic for addressing the growing needs of the more than 185,000 patients living with metastatic castration-resistant disease today1.”
Photo by: Johnson & Johnson Media Center
